REVVITY, INC. (RVTY) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended September 28, 2025. Revvity, Inc. operates as a leading provider of health science solutions with two reportable segments: Life Sciences (Life Sciences Solutions and Software) and Diagnostics (Immunodiagnostics and Reproductive Health). Effective in fiscal year 2025, the company reorganized its operating model, integrating the majority of its Applied Genomics business into the Life Sciences segment.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | YTD 9M 2025 | YTD 9M 2024 |
|---|---|---|---|---|
| Total Revenue | $698.9 million | $684.0 million | $2,084.0 million | $2,025.7 million |
| Gross Margin | 53.6% | 56.3% | 54.8% | 55.6% |
| Operating Income | $81.9 million | $98.2 million | $244.9 million | $228.0 million |
| Net Income | $46.7 million | $94.4 million | $142.8 million | $175.7 million |
| Diluted EPS | $0.40 | $0.77 | $1.21 | $1.42 |
| Cash & Equivalents | $931.4 million | N/A | N/A | N/A |
| Total Debt (Carrying) | $3.21 billion | N/A | N/A | N/A |
| Operating Cash Flow (9M) | $407.0 million | N/A | N/A | $489.5 million |
Material Changes vs. Prior Period
- Revenue Growth: Q3 revenue increased 2% year-over-year, driven by a 3% increase in the Diagnostics segment (Reproductive Health and Immunodiagnostics) and a 1% increase in Life Sciences (Software growth offset by a decline in Life Sciences Solutions).
- Margin Compression: Gross margins decreased 266 basis points in Q3 and 72 basis points YTD. Management attributes this to increased tariffs, unfavorable foreign exchange rates, and product mix shifts.
- Profitability Decline: Net income dropped significantly in Q3 ($46.7M vs $94.4M) due to lower operating income and higher interest/other expenses. Operating income fell 17% in Q3.
- Debt Structure: The company repaid senior unsecured notes maturing in September 2024, reducing interest expense. However, the 1.875% Notes due in 2026 (€500M principal) are now classified as current liabilities.
- Share Count: Weighted average shares outstanding decreased from 123.0 million (Q3 2024) to 115.5 million (Q3 2025) due to aggressive share repurchases.
Guidance, Outlook, and Risks
- Tariff Impact: Management estimates that recently enacted tariffs could increase cost of revenue by approximately $25 million for the fiscal year, resulting in a $20 million decrease to gross margin. Mitigation strategies include manufacturing optimization and selective pricing.
- Tax Outlook: The effective tax rate is expected to be approximately 20% for fiscal year 2025, higher than the prior year due to the absence of favorable prior-year true-ups. The "One Big Beautiful Bill Act" (OBBBA) is not expected to materially impact the 2025 provision.
- Capital Allocation: The company terminated its previous $1.0 billion repurchase program on October 23, 2025, and immediately authorized a new $1.0 billion program expiring in October 2027. Dividends remain at $0.07 per share.
- Risks: Key risks include global economic conditions, supply chain disruptions, foreign currency volatility, and the potential impairment of significant intangible assets ($9.0 billion net carrying value). The company faces environmental liabilities estimated at $11.1 million.
Investor Verification Checklist
- Tariff Mitigation: Verify the effectiveness of pricing actions and supply chain shifts in offsetting the projected $20 million gross margin hit from tariffs.
- Debt Maturity: Confirm the funding source for the €500M (approx. $584M) 2026 Notes maturing in July 2026, which are currently classified as current liabilities.
- Intangible Assets: Monitor the annual goodwill impairment test scheduled for November 2025, given the $9.0 billion net intangible asset base and margin pressures.
- Software Growth: Assess the sustainability of Software revenue growth ($8.9M increase in Q3) as a counterbalance to declines in Life Sciences Solutions.
- Working Capital: Review the $97.9 million net cash decrease in working capital for the nine-month period to ensure it is not a recurring trend affecting liquidity.